Advances in Early Cancer Detection: Insights for Managed Care Professionals

Advances in Early Cancer Detection: Insights for Managed Care Professionals

Faculty Presenter

Robert Mancini, PharmD, BCOP, FHOPA
BMT Pharmacy Program Coordinator & PGY2 Residency Director
St. Luke’s Cancer Institute
Boise, Idaho

Adjunct Clinical Instructor – Oncology
Idaho State University College of Pharmacy
Meridian, Idaho
 
Program Description

Cancer remains the leading cause of death in the United States among those younger than 80 years. In 2018, more than 18 million new cases of cancer were diagnosed, of which nearly 5 million cases of breast, cervical, colorectal, and oral cancers could have been detected sooner and treated more effectively. Much of this can be attributed to a lack of application of known interventions as well as a lack of guideline-recommended screening procedures for many cancers. When diagnosed after they have progressed to late stages, chances for survival are much lower, treatment is more complex, and overall survival is reduced. Those who receive an early-stage cancer diagnosis have 2 times fewer costs and 3 times higher 5-year survival rate compared with those with late-stage disease. Early detection and diagnosis of cancer with an array of technological advances in next-generation sequencing has the potential to dramatically change the landscape of cancer diagnosis and management. This activity will provide managed care professionals with an overview of trial data related to multicancer screening tests under development and discuss important considerations when incorporating such technologies into screening policies and procedures.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: October 15, 2020
Expiration date:  October 28, 2021
Estimated time to complete activity: 1.0 hour
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Examine the burden associated with cancer in the United States and current guideline-recommended cancer screening practices.
• Explore clinical trial data for emerging multicancer detection blood testing.
• Explain managed care considerations for incorporating novel cancer detection technology into screening pathways and algorithms.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.1 CEU) under the ACPE universal activity number 0290-0000-20-295-H01-P. The activity is available for CE credit through October 28, 2021.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Robert Mancini, PharmD, BCOP, FHOPA, has the following relevant financial relationship with a commercial interest to disclose:
Speakers Bureau: Takeda

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Ann Marciano; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms